Literature DB >> 25787726

[Is the use of placebo as control group in MS drug trials still appropriate?].

A Haghikia1, R Gold.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25787726     DOI： 10.1007/s00115-015-4283-z

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


× No keyword cloud information.
  10 in total

1.  Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS.

Authors:  F D Lublin; S C Reingold
Journal:  Ann Neurol       Date:  2001-05       Impact factor: 10.422

2.  [Pegylated interferon beta 1a. A new therapy option for treatment of relapsing-remitting multiple sclerosis].

Authors:  V I Leussink; C Warnke; B Tackenberg; H Wiendl; B C Kieseier
Journal:  Nervenarzt       Date:  2015-04       Impact factor: 1.214

3.  Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment.

Authors:  C H Polman; S C Reingold; F Barkhof; P A Calabresi; M Clanet; J A Cohen; G R Cutter; M S Freedman; L Kappos; F D Lublin; H F McFarland; L M Metz; A E Miller; X Montalban; P W O'Connor; H Panitch; J R Richert; J Petkau; S R Schwid; M P Sormani; A J Thompson; B G Weinshenker; J S Wolinsky
Journal:  Neurology       Date:  2008-03-25       Impact factor: 9.910

4.  Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.

Authors:  Peter A Calabresi; Bernd C Kieseier; Douglas L Arnold; Laura J Balcer; Alexey Boyko; Jean Pelletier; Shifang Liu; Ying Zhu; Ali Seddighzadeh; Serena Hung; Aaron Deykin
Journal:  Lancet Neurol       Date:  2014-04-30       Impact factor: 44.182

5.  Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

Authors:  Alasdair J Coles; Edward Fox; Anton Vladic; Suzanne K Gazda; Vesna Brinar; Krzysztof W Selmaj; Ann Doan-Do Bass; Daniel R Wynn; David H Margolin; Stephen L Lake; Susan Moran; Jeffrey Palmer; M Shelton Smith; D Alastair S Compston
Journal:  Lancet Neurol       Date:  2011-04       Impact factor: 44.182

6.  Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.

Authors:  Daniel Wynn; Michael Kaufman; Xavier Montalban; Timothy Vollmer; Jack Simon; Jacob Elkins; Gilmore O'Neill; Lauri Neyer; James Sheridan; Chungchi Wang; Alice Fong; John W Rose
Journal:  Lancet Neurol       Date:  2010-02-15       Impact factor: 44.182

7.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

8.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Authors:  Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Bhupendra O Khatri; Xavier Montalban; Jean Pelletier; Ruggero Capra; Paolo Gallo; Guillermo Izquierdo; Klaus Tiel-Wilck; Ana de Vera; James Jin; Tracy Stites; Stacy Wu; Shreeram Aradhye; Ludwig Kappos
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

9.  Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

Authors:  Ralf Gold; Gavin Giovannoni; Krzysztof Selmaj; Eva Havrdova; Xavier Montalban; Ernst-Wilhelm Radue; Dusan Stefoski; Randy Robinson; Katherine Riester; Jitesh Rana; Jacob Elkins; Gilmore O'Neill
Journal:  Lancet       Date:  2013-04-04       Impact factor: 79.321

Review 10.  Therapies for multiple sclerosis: translational achievements and outstanding needs.

Authors:  Aiden Haghikia; Reinhard Hohlfeld; Ralf Gold; Lars Fugger
Journal:  Trends Mol Med       Date:  2013-04-10       Impact factor: 11.951
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.